The prevalence of non-alcoholic fatty liver disease (NAFLD) is continually increasing due to
the global obesity epidemic. NAFLD comprises a systemic metabolic disease accompanied …

Conclusions Comorbidities, including coronary artery disease, cerebrovascular disease and
chronic obstructive pulmonary disease, are more prevalent in hospitalized Chinese patients …

Nonalcoholic fatty liver disease (NAFLD) is increasing in prevalence worldwide and has
been identified as a risk factor for cirrhosis and hepatocellular carcinoma. However, there is …

Obesity and type 2 diabetes are frequently complicated by excess fat accumulation in the
liver, which is known as nonalcoholic fatty liver disease (NAFLD). In this context, liver …

Hepatocellular carcinoma (HCC) is a major cancer burden worldwide with increasing
incidence in many developed countries. Super-enhancers (SEs) drive gene expressions …

Background: NAFLD has become the leading cause of chronic liver disease worldwide
afflicting about one quarter of the adult population. NASH is a severe subtype of NAFLD …

Abstract Non-Alcoholic Fatty Pancreas disease (NAFPD), characterized by fat accumulation
in pancreatic tissue, is an emerging clinical entity. However, the clinical associations, the …

Background & Aims Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic
steatohepatitis (NASH) are emerging as leading causes of liver disease worldwide …

The Innovative Medicines Initiative (IMI) is a public-private partnership between the
European Union and the European pharmaceutical industry. Born of the necessity to foster …

Non-alcoholic steatohepatitis (NASH) is an inflammatory disorder that is characterized by
chronic activation of the hepatic inflammatory response and subsequent liver damage. The …